Top

CNS Drugs

Published in:

01-06-2007 | Adis Profile Report

Selegiline Transdermal System in Major Depressive Disorder

Profile Report

Authors: James E. Frampton, Greg L. Plosker

Published in: CNS Drugs | Issue 6/2007

Excerpt

Major depressive disorder (MDD) is a highly prevalent and disabling condition.[4] It has a lifetime prevalence of ≊16% in the US;[5] worldwide, it is the leading cause of non-fatal disease burden (accounting for 12% of all years lived with disability) and the fourth leading cause of total disease burden (accounting for 4.4% of all disability-adjusted life-years).[6] Treatment modalities include psychotherapy, pharmacotherapy, combined psychopharmacotherapy or electroconvulsive therapy. Of these, pharmacotherapy is the preferred choice for moderate-to-severe episodes of depression, about half of which will show improvement.[7] …

2 The use of trade names is for product identification purposes only and does not imply endorsement.

Frampton JE, Plosker GL. Selegiline transdermal system in the treatment of major depressive disorder. Drugs 2007; 67(2): 257–65PubMedCrossRef

Bodkin JA. Selegiline transdermal system in the treatment of major depressive disorder: a viewpoint. Drugs 2007; 67(2): 266–7CrossRef

Baghai TC. Selegiline transdermal system in the treatment of major depressive disorder: a viewpoint. Drugs 2007; 67(2): 266–7CrossRef

Holtzheimer PE3rd, Nemeroff CB. Advances in the treatment of depression. NeuroRx 2006 Jan; 3(1): 42–56PubMedCrossRef

Kessler RC, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun 18; 289(23): 3095–105PubMedCrossRef

Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004 May; 184: 386–92PubMedCrossRef

Mann JJ. The medical management of depression. N Engl J Med 2005 Oct 27; 353(17): 1819–34PubMedCrossRef

Patkar AA, Pae C-U, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr 2006; 11(5): 363–75PubMed

Robinson DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull 2002 Summer; 36(3): 124–38PubMed

10.

Anderson IM, Nutt DJ, Deakin JFW, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000; 14(1): 3–20PubMedCrossRef

11.

American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000 Apr; 157(4 Suppl.): 1–45

12.

Thase ME. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression. J Clin Psychiatry 2006 Apr; 67(4): 671–2PubMedCrossRef

13.

Mahmood I. Selegiline transdermal system Somerset. Curr Opin Investig Drugs 2002 Aug; 3(8): 1230–3PubMed

14.

Preskorn SH. Why the transdermal delivery of selegiline (6 mg/ 24 hr) obviates the need for a dietary restriction of tyramine. J Psychiatric Practice 2006 May; 12(3): 168–72CrossRef

15.

EMSAM® (selegiline transdermal system) continuous delivery for once-daily application: prescribing information. Tampa (FL): Somerset Pharmaceuticals Inc., 2006 Apr

16.

Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002 Nov; 159: 1869–75PubMedCrossRef

17.

Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003 Feb; 64: 208–14PubMedCrossRef

18.

Feiger AD, Rickels K, Rynn M, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006 Sep; 67(9): 1354–61PubMedCrossRef

19.

Amsterdam JD, Bodkin JA. Selegiline transdermal system (STS) in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006; 26: 1–8CrossRef

20.

Quitkin FM, Stewart JW, McGrath PJ, et al. Atypical depression: unipolar depressive subtype with preferential response to MAOIs. In: Kennedy SH, editor. Clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press, 1994

21.

Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910–6PubMed

22.

Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression: a retrospective study. J Affect Disord 2005; 89(1–3): 183–8PubMedCrossRef

23.

IMS Health national prescription audit; 12/04-11/05 [online]. Available from URL: http://www.imshealth.com [Accessed 2006 Jan 20

Title: Selegiline Transdermal System in Major Depressive Disorder
Profile Report
Authors: James E. Frampton
Greg L. Plosker
Publication date: 01-06-2007
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 6/2007
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200721060-00007

At a glance: The STEP trials

Springer Medicine

Selegiline Transdermal System in Major Depressive Disorder

Profile Report

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2007

Mood and Anxiety Disorders in Patients with Myasthenia Gravis

Long-Acting Formulations of Atypical Antipsychotics

Assessing the Role of Drugs in Suicidal Ideation and Suicidality

Impact of Psychotropic Medications on Simulated Driving

Effect of HMG-CoA Reductase Inhibitors on β-Amyloid Peptide Levels

Oral Disease-Modifying Treatments for Multiple Sclerosis